SDZ 208-912

SDZ 208-912 is a dual-action 5-HT1A/2 receptor agonist and dopamine D1 receptor antagonist. SDZ 208-912 exhibits partial dopamine agonism and atypical neurosedative effects in rodent models. SDZ 208-912 can be used in research on neurological disorders such as schizophrenia[1].

101000-49-1

12352005

5-HT Receptor; Dopamine Receptor

GPCR/G Protein; Neuronal Signaling

Neurological Disease

ClC1=C2C3=C(N1)C=CC=C3[C@]4([H])[C@@](N(C[C@H](C4)NC(C(C)(C)C)=O)C)([H])C2

C20H26ClN3O

359.89

[1]Coward DM, et al. Partial dopamine-agonistic and atypical neuroleptic properties of the amino-ergolines SDZ 208-911 and SDZ 208-912. J Pharmacol Exp Ther. 1990 Jan;252 (1) :279-85.|[2]Coward DM, et al. Partial dopamine-agonistic and atypical neuroleptic properties of the amino-ergolines SDZ 208-911 and SDZ 208-912. J Pharmacol Exp Ther. 1990 Jan;252 (1) :279-85.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-19029/

Reference compound1

No Development Reported